Synaffix’s site-specific–conjugation and payload-enhancement technologies are improving the safety and efficacy of antibody-drug conjugates (ADCs) without the need for antibody engineering.

Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...

Drugs are classified into different groups according to their chemical characteristics, structure and how they are used to treat specific disease. Medindia brings you the list of eighty six such ...